Advertisement

Targeting DNA

After 20 years of high-profile failure, gene therapy is finally well on its way to clinical approval.

By | June 1, 2012

GETTYIMAGES, CRISTIAN BAITG (TARGET AND EYE); ISTOCKPHOTO.COM, PIAL HOVIK (DNA HOOP)

The concept is simple: if a mutated gene is causing a problem, replace or supplement it with a new, accurate copy. In theory, such a strategy could not just treat, but cure countless human genetic diseases. In practice, however, developing safe and effective gene therapies has not been easy. Even when identifying a disorder’s genetic basis is fairly straightforward, finding the appropriate delivery vector to target the diseased tissues in the body, while avoiding unintended consequences, has challenged would-be gene therapists for more than 20 years. But more and more researchers are convinced that the technique is on the brink of becoming a common medical practice.

Clearly gene therapy is going to be a therapeutic pathway forward for a whole range of diseases.
—Katherine High, University of Pennsylvania
School of Medicine

“It’s an incredibly exciting time for the field,” says researcher and medical oncologist David Kirn, founder, president, and chief medical officer at Jennerex, Inc., a San Francisco-based biotherapeutics company that develops and commercializes oncolytic drugs. In the last year alone, he says, major breakthroughs have been published for the use of gene therapy in patients with hemophilia, solid tumors, and leukemia, not to mention the dozens of trials yielding positive results for gene therapies to treat various types of blindness. “It’s just remarkable,” he says. “These decades of work are suddenly really paying off.”

Fits and starts

It hasn’t always been such high times for gene therapy, however. The field was booming in its early days, with approvals for gene therapy clinical trials rising exponentially from the first one in 1989 to 116 in 1999. But that year, gene therapy trial participant Jessie Gelsinger, a relatively healthy 18-year-old who had an unusually mild form of liver disease caused by mutations in a gene on the X chromosome, died 4 days after receiving an injection of an adenovirus carrying an unmutated copy of the gene meant to correct his condition. The viral vector apparently triggered a massive immune response that caused multiple organ failure and brain death.

Infographic: Delivering New Genes View full size JPG | PDF
Infographic: Delivering New Genes
View full size JPG | PDF
LUCY READING-IKKANDA

Then, starting in 2002, reports from Paris and London told of patients developing a leukemia-like disease following treatment in clinical trials for a rare autoimmune disorder called severe combined immunodeficiency (SCID), or “bubble-boy” disease. SCID patients lack a functioning immune system, and thus must live in highly sterile conditions to prevent life-threatening infections. The studies started out extremely well: most of the infant boys were able to live relatively normal lives, no longer confined to their “bubbles.” The trials were hailed as the first unequivocal gene therapy success.

But in the years that followed, 5 of the 20 trial patients developed a leukemia-like disease—an effect that was traced to the retroviral vector used to deliver the corrective gene to bone marrow cells ex vivo. The vector had inappropriately inserted the gene into the babies’ genomes close to a proto-oncogene involved in white blood cell proliferation, activating the gene and triggering a flood of T cells. After the second child fell ill, the US Food and Drug Administration suspended 30 US trials using the same retrovirus, or about 15 percent of the 200 gene therapy trials under way at that time—a move the agency called a precautionary measure. Of the five patients that developed leukemia, one died; the rest are in remission.

Events like these had “a big negative impact in the field,” recalls molecular cell biologist Mien-Chie Hung of the University of Texas MD Anderson Cancer Center. Interest in gene therapy started to wane, and treatments that might have been expected to hit the market years ago are still plugging through the clinical trial process.

But things are looking up. Just last year, for example, researchers published long-term survival data for two UK gene therapy trials for SCID: the original London trial for X-linked SCID (SCID-X1) and a second trial for adenosine deaminase (ADA) SCID.[1. H.B. Gaspar et al., “Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency,” Sci Transl Med, 3:97ra79, 2011.],[2. H.B. Gaspar et al., “Hematopoietic stem cell gene therapy for adenosine deaminase–deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction,” Sci Transl Med, 3:97ra80, 2011.] In both trials, the researchers had extracted the patients’ bone marrow, inserted a functioning copy of the disease-causing gene, and infused the altered cells back into the patients. The impressive bottom line: up to 9 years after treatment, 14 of the 16 children treated have had their immune systems restored and have been able to live relatively normal lives free of any bubbles. “These kids were living in bubbles with a life expectancy of less than 20 years; they had no quality of life,” says Kirn. “And now many of them are essentially cured. I mean, it’s a medical miracle.”

Many other gene therapy trials are currently underway—and yielding positive results—for numerous other diseases, including various forms of hereditary blindness, HIV, hemophilia, neurodegenerative diseases, and a variety of cancers. Though no gene therapies have yet received FDA approval, nearly 2,000 clinical trials have been initiated in the last 5 years alone, according to clinicaltrials.gov, many with seemingly miraculous results and—thanks to improved vectors and techniques—none of the devastating side effects that plagued the field in its earlier days.

“There is a lot of exciting information coming out right now,” says Howard Hughes Medical Institute investigator Katherine High of the University of Pennsylvania School of Medicine and the Children’s Hospital of Philadelphia, who coauthored a report published last December of a successful gene therapy for hemophilia B.[3. A.C. Nathwani et al., “Adenovirus-associated virus vector-mediated gene transfer in hemophilia B,” N Engl J Med, 365:2357-65, 2011.] Loading up an adenovirus-associated virus with a gene encoding a functional version of the clotting agent known as factor IX, researchers in the United Kingdom infused the vector into six men with severe hemophilia B. A single treatment was enough to increase clotting factor IX to levels that, while still well below normal, enabled sufficient clotting to allow four of the patients to discontinue factor IX replacement therapy altogether, and the other two to receive factor IX injections less frequently. “To me, clearly [gene therapy] is going to be a therapeutic pathway forward for a whole range of diseases,” predicts High.

An eye on gene therapy

Nowhere has gene therapy made more of a splash than in blindness research. Because the eye is an immune-privileged site, injecting viruses is unlikely to result in the sorts of immune complications that killed Gelsinger in 1999. Indeed, there are some 23 completed and ongoing clinical trials for various types of blindness disorders, and no serious side effects have been reported.

We’re entering a golden age here of genetic therapies and viral therapies.
—David Kirn, Jennerex, Inc.

“It’ll be a few years” before these therapies reach the market, says University of Florida molecular virologist William Hauswirth. But the results so far are “bordering on spectacular as far as improving vision in the patients,” he adds.

In a recent, 3-year follow up on 15 patients with Leber congenital amaurosis (LCA), a degenerative retinal disease that causes childhood blindness, Hauswirth and his colleagues found that within the area of the retina they are targeting for treatment, “patients have gained light sensitivity from as little as to 200-fold to as much as 60,000-fold,” he says. Twelve of the patients have also demonstrated significant improvement in visual acuity, reading an extra three lines lower on an eye chart, and in 13 of the patients, their pupils constricted when exposed to light as much as 100-fold dimmer, a more objective measure of light sensitivity.[4. S.G. Jacobson et al., “Gene therapy for Leber congenital amaurosis caused by RPE65 mutations,” Arch Ophthalmol, 130:9-24, 2012.]

This particular group of patients was treated with a modified adeno-associated virus (AAV) carrying the gene RPE65, which helps metabolize a form of vitamin A that allows rods and cones to function. The modified virus was injected behind the eye, directly under the retina, where the corrective gene entered some 15 to 20 percent of cells in the retinal pigment epithelium (RPE), the nourishing cell layer just beneath the retinal visual cells.

The AAV is a popular choice for gene therapies now in development. It is a nonpathogenic virus that usually elicits no noticeable immune response, and does not integrate into the host genome, meaning there is little risk of triggering disease-causing mutations, via the activation of an oncogene, for example. The virus simply delivers the gene to the cell’s nucleus, where it forms small circles of DNA called episomes that can be expressed under the control of promoters, also delivered by the virus. “AAV is by far the most successful vector for many applications in disease so far,” says Hauswirth.

The disadvantage to this strategy is that if the replacement gene is not integrated into the cell’s DNA, it will be lost when the cell divides, as circular DNA is not replicated with the rest of the nuclear genome. But because retinal cells are extremely long-lived, a nonintegrating virus is perfectly suitable for treating eye diseases.

Infographic: Messing with HIV View full size JPG | PDF
Infographic: Messing with HIV
View full size JPG | PDF
LUCY READING-IKKANDA

The main factor limiting the utility of AAVs as gene vectors is their small size—no larger than a nanoparticle. This means they can only carry about 4.7 kilobases of DNA, and that must include any promoters needed to regulate the expression of the therapeutic DNA. This works just fine for Hauswirth’s RPE65replacement therapy, but many other ocular diseases, as well as diseases of other body systems, result from mutations in genes that are quite a bit larger.

For therapies to correct these disorders, researchers must turn to other options. Most early experiments in gene therapy for eye diseases used adenoviral vectors, which, like AAVs, are nonintegrating vectors, but, with a 36-kilobase genome, provide much more space for therapeutic DNA. However, because many humans already carry antibodies to adenovirus, the great drawback of this approach is the risk of immunotoxicity, which can disable the therapeutic vector or cause side effects in the host. It was an extreme reaction to an adenoviral vector that killed Jesse Gelsinger. Because adenoviruses are efficient at entering many cell types and delivering the goods, they are targets of intensive research to make them safer for the treatment of cancer, diabetes, HIV, and genetic diseases.

Lentiviruses, a type of RNA retrovirus, also have a sizeable carrying capacity: some 9 kilobases of genetic material. “You only have to delete a few genes to get lentivirus to carry twice as much as AAVs,” Hauswirth says. And in contrast to adenoviruses and AAVs, they do integrate into the genome, making them efficient at delivering and establishing stable high levels of transgene expression in both dividing and nondividing cells. While they cannot yet be targeted to integrate at specific sequences, they don’t gravitate to oncogenes or growth-related genes as some other retroviral vectors do, and are at the forefront of the race to market.

Oxford BioMedica, for example, is using its integrating lentiviral vector, called LentiVector, to deliver treatments for a variety of eye diseases, including wet age-related macular degeneration, Stargardt disease, Usher syndrome, and corneal graft rejection. All of these therapies are in phase I/II development in partnership with Sanofi, and “the results we have seen in our clinical trials to date have been encouraging,” says the company’s chief scientific officer, Stuart Naylor. “We believe it is only a matter of time before a gene therapy is approved for the market.”

“The field is running at the speed of light,” agrees veterinary ophthalmologist and basic vision scientist Gustavo Aguirre of the University of Pennsylvania. “We’re beyond anything that we thought in the ’90s.”

Targeting cancer: pluses and minuses

As with gene therapies for other diseases, the technique’s use in treating cancer is gathering steam. Oncolytic viruses that target and destroy tumor cells are being combined with gene therapy techniques to provide tools to jack up those viral vectors with more potent genetic loads. “The concepts have been around for centuries—the fact that viruses can certainly destroy cancer cells,” says Jennerex’s Kirn. Now, “in addition to replicating and expressing viral genes, we also express therapeutic transgenes and imaging genes.”

Now gene therapy is actually fulfilling the promise that people said it would have.
—Carl June, Penn Medicine

Jennerex is developing a vaccinia virus vector called JX-594, for example, to deliver genes that activate the epidermal growth factor receptor (EGFR)/Ras pathway in cancer cells, resulting in cell lysis and increased anticancer immunity. In multiple phase I and II trials involving numerous cancer types, including liver, colon, kidney, lung, and melanoma, JX-594 has shrunk tumors and is well-tolerated by patients. Last November, Jennerex researchers announced that advanced liver cancer patients receiving JX-594 in a phase II trial had a 60 percent decreased risk of death after 1 year as compared to controls.

Another engineered oncolytic virus nearing clinical approval is OncoVEX, developed by Massachusetts-based biotech BioVex, which last year partnered with Amgen in a deal that could be worth $1 billion. The drug, named last year as one of FierceBiotech’s 10 promising late-stage cancer drugs, is a special strain of the Herpes simplex type 1 (HSV-1) virus that carries an immune-boosting component. Results of a phase II trial for metastatic melanoma announced in 2009 showed that 26 percent of 50 patients responded to treatment, with 8 completely recovering,[5. H.L. Kaufman et al., “Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma,” Annals of Surgical Oncology, 17:718-30, 2010.] and the treatment is now in phase III trials. OncoVex has also shown activity against breast and pancreatic cancers in phase I trials.

And these successful examples are not the outliers. “We’re entering a golden age here of genetic therapies and viral therapies,” says Kirn.

Getting to this point took some careful planning, however, to avoid the destruction of healthy tissue. “The most important thing is you need a specific target,” says MD Anderson’s Hung. Most oncolytic viruses are designed to target a receptor or surface protein that is overexpressed on cancer cells, to increase the chance that the viruses enter and kill only diseased tissue. But this, of course, requires that tumors have unique surface antigens. “That’s the ideal situation—to find something on tumor cells that’s not on normal cells,” says hematologist-oncologist David Porter of the University of Pennsylvania Medical Center. “That’s not possible in most tumors,” he says, which may be part of “the reason this field has been so slow to develop.”

So Hung is taking a slightly different approach. Instead of focusing on viruses that selectively target cancer cells, or rigging them to do so, Hung and his colleagues have designed a vector, dubbed VISA, that goes everywhere, but whose package is only activated in cancer cells. “DNA by itself does not cause side effects—every cell has DNA,” says Hung. “It [is] the gene product.”

The VISA vector is designed to amplify expression of the genes it carries under the control of a promoter that is expressed at higher levels in tumors. “Then whatever DNA we inject into the bloodstream may go anywhere, but will express only in cancer cells,” Hung explains. In 2007, the researchers used VISA, equipped with a modified apoptosis promoter, called BikDD, to knock down pancreatic cancer in mice.[6. X.M. Xie et al., “Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models,” Cancer Cell, 12:52-65, 2007.] The protocol is currently being tested for safety in a phase I trial, and Hung and his colleagues are now applying the VISA vector to breast cancer, with promising preclinical results coming out just last year,[7. J.-Y. Lang, “BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment,” Cancer Cell, 20:341-56, 2011.] as well as to lung, ovarian, and liver cancers.

Yet another gene therapy strategy for fighting cancer involves the collection of immune cells from patients, insertion of genetic material that essentially trains the cells to target and kill cancer, and the infusion of those cells back into the patients. “The idea is to somehow modify a person’s own T cells so they can now recognize and attack tumor cells that they otherwise aren’t able to kill,” says Porter. “By definition, if someone has a tumor, their T cells aren’t able to kill [it].”

In 2011, Porter, along with Carl June and other colleagues at Penn Medicine, reported that they had engineered a patient’s T cells ex vivo to target chronic lymphocytic leukemia (CLL) cells, marking the first gene therapy success for advanced cancer. The researchers used a lentivirus to insert a chimeric antigen receptor targeting CD-19—a molecule found on “all CLL cells but only a small subset of normal cells,” Porter says—as well as two potent signaling domains, which help the T cells survive longer and activate strongly at the appropriate time. Last August, the researchers published the results of a phase I trial, in which two participants had been in complete remission for up to a year, and a third was showing signs of a strong antitumor response.[8. D.L. Porter et al., “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” N Engl J Med, 365:725-33, 2011.],[9. M. Kalos et al., “T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia,” Sci Transl Med, 3:95ra73, 2011.] In addition, some of the cells persisted as memory T-cells, primed to attack in the event of a recurrence.

However, researchers had to weigh the fact that the engineered T cells could also attack healthy tissue. CLL is characterized by the abnormal proliferation of B cells, but it’s not just the malignant B cells that express CD-19; normal B cells also carry the antigen on their surface. As a result of the lentiviral therapy, patients experienced a loss of B cells down to undetectable levels. “[This] potentially makes them susceptible to infections,” Porter notes. But he is not worried. No patients have contracted any unusual infections in a year and a half of follow up, and antibody replacement is always an option. “We think it is possible to live without B cells,” he says. But it’s an important concern when developing such therapies, he adds. “If you were to target a cell that was also on the lining of your heart or your lungs or your intestines, that wouldn’t be safe.”

This strategy is now being applied to diverse cancer types, including mesothelioma (a type of lung cancer), breast cancer, ovarian cancer, and melanoma, all in early-stage trials. With the improved ability to grow T cells in the lab and make better-targeted viral vectors, “the field is really growing,” Porter says. “You can now use this technology to target really almost anything you can identify as a unique target.”

The gene’s the limit

In 2007, Timothy Brown, a 40-year-old American living in Berlin, had a relapse of acute myeloid leukemia and received a bone-marrow transplant to boost his immune function. Because he was also living with HIV, his doctor chose a donor with a mutation in both copies of the CCR5 gene, which encodes an HIV co-receptor carried on the surface of T cells to which HIV usually must bind in order to enter the cells. People with mutations in both copies of the CCR5 gene are resistant to HIV infection. A year later, Brown relapsed again, and once again received a stem-cell transplant from the CCR5-mutant donor. Finally, he beat his cancer, and as of 2010, his HIV was still at undetectable levels, despite his having discontinued immune-suppressive treatment.[10. G. Hütter et al., “Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation,” N Engl J Med, 360:692-98, 2009.] By most accounts, Brown is the first person to have been cured of an HIV infection.

The impressive result validated Sangamo Biosciences’ efforts to design a gene therapy to modify the CCR5 gene of HIV patients’ T cells. This is done ex vivo, using an adenovirus vector that delivers its package to T cells carrying the glycoprotein receptor CD4, after which the cells are infused back into the patients. This strategy is different from corrective gene therapies in that it’s taking a normal gene and replacing it with a defective copy. In this case, it’s important to not just supplement the existing copies of the gene, which would continue to produce normal CCR5 receptors, but to render the gene defective so the cells present no CCR5 receptors on their surfaces. To do this, Sangamo researchers are using zinc-finger nucleases, which act as molecular scissors to edit the existing gene.

“What we’re doing is . . . actually editing the gene in a way that changes its nucleic acid sequence,” says Sangamo CEO Edward Lanphier. “It’s quite different from classical gene therapy, where you’re just essentially putting in the coding region of a gene.”

Preliminary results of these trials, presented at the Conference on Retroviruses and Opportunistic Infections (CROI) last March, have shown that all 21 HIV patients treated with one infusion of their own modified T cells have tolerated the treatment well, and show increased CD4+ T cell counts more than a year later. And when six of the patients took a planned 12-week hiatus from antiretroviral treatment, they had lowered HIV viral loads that correlated with the levels of circulating modified CD4+ T cells. One patient, who naturally carried one copy of the defective CCR5 gene, had undetectable viral levels.

The results are promising, says June, who is heading up one of two phase I trials of the therapy, and who hopes that such gene-editing techniques will be applicable to a wide range of diseases. “We’re trying to make a good gene bad in the case of the HIV, so that the cells aren’t infected,” he says, “but you can do the inverse, which is to take a bad gene and fix it.” Such genome editing would be permanent, and leaves the gene under the control of natural promoters, making it more therapeutically appealing, says Lanphier. “The downstream biology of changing the endogenous gene is fundamentally different—and quite frankly, from a therapeutic outcome, superior—than conventional gene therapy approaches,” he says.

Other novel gene therapy strategies are also in development, such as employing transiently expressed RNA to confer a therapeutic benefit, and using cell- and protein-based delivery systems instead of viral vectors. With these and other techniques, researchers have recently demonstrated successes in treatments for hemophilia, with promising trial results released last December; numerous neurodegenerative diseases, such as Parkinson’s and Huntington’s; and autoimmune disorders, such as SCID, among others. And importantly, there have been no more safety scares like the ones that rattled the field a decade ago.

“The history of medicine says every new technology starts with a great idea and then requires hard work and optimization,” says Kirn. “And I think that’s exactly what’s happened with gene therapy. Hurdles were identified—and there’s always hurdles once you get into a complex human disease situation—and they’ve been addressed.”

“The concepts aren’t that much different than they were early on, but the tools are much better,” agrees June. “Now [gene therapy] is actually fulfilling the promise that people said it would have.”

Advertisement
The Scientist
The Scientist

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Hasan Abbas

Hasan Abbas

Posts: 1457

June 6, 2012

The dream of conquering death may become a reality soon.

Avatar of: help find a cure

help find a cure

Posts: 1457

June 6, 2012

check out this research group ....out of the University of Washington
http://boinc.bakerlab.org/rose...

http://fold.it/portal/


From Stanford University and Stanford University Medical Center
http://folding.stanford.edu/En...

Avatar of: Goldenhine

Goldenhine

Posts: 1457

June 6, 2012

I suppose there is only one compound question left.  How much will these approaches cost per patient when they reach the market and who will pay for it.  If the answer is $100k-$200k, I wonder if the scientists have taken that into account.  

Avatar of: oussu

oussu

Posts: 7

June 7, 2012

It is not the scientists' role to consider final patient pricing and and the responsible party for paying it.  That is the role of the patient, insurance, governments (where applicable, those in Europe for example), and the company that ultimately markets and sells the treatment.  Scientists should be mindful of developing cost-effective processes for production whenever possible and all companies drive that anyway, but scientists have little impact ultimately on the final price of a marketed therapeutic.  There are multiple protein replacement therapies on the market currently that cost $200k-$300k per YEAR, and those costs are driven primarily by decisions of the insurance companies and manufacturing company (e.g., business development).

Avatar of: Ichha Purak

Ichha Purak

Posts: 1457

June 7, 2012

 In Targetting DNA or normal funtional gene to replace mutated probably non funtional gene, the role of  Viral Vector as adenoviruses are efficient and promosing and shows great prospect .

Avatar of: T

T

Posts: 1457

June 12, 2012

Let the scientists do their thing! Pricing will not be an issue in the medium or long term. If the technique or compound used is patentable, the patents eventually expire and the treatment is there for all to use at market price. If the technique is not patentable, and the treatment is useful and has value but is expensive, companies and entrepreneurs will inexorably drive the price down. Net net, patients benefit, big time.

Avatar of: Lucy Huang

Lucy Huang

Posts: 1457

June 17, 2012

I'm surprised that this book was not mentioned:
http://www.amazon.com/The-Fore...

Avatar of: TheSciAdmin

TheSciAdmin

Posts: 56

June 22, 2012

 Hi Lucy,

Thanks for reading. Actually we reviewed The Forever Fix in our March issue. http://the-scientist.com/2012/....

It's a great book!

The Scientist

June 26, 2012

The author got it wrong. The AAV vector does intergate into the genome.

Avatar of: Ellen Hunt Phd

Ellen Hunt Phd

Posts: 1457

June 26, 2012

That's correct. It's normal site is on chromosome 19. See: Site-specific integration by adeno-associated virus. PNAS, Vol. 87, pp. 2211-2215, 1990

However, any retrovirus will deliver its genes and not integrate if the ITRs and integrase are removed from it. So it can.

Avatar of: Brian Hanley

Brian Hanley

Posts: 66

June 26, 2012

Cost of production per treatment will be around $100 base cost with handling. The big costs are in GMP production which can raise an external bid from around $10,000 - $20,000 of 5000 doses acceptable for animals, to $600,000 for GMP certification for the same thing. At $600K the dose cost for 5000 doses is $120 per dose.  (That GMP cost is much to high in my opinion, but it's still not a huge cost.) Assuming cost of money and freezer time for an investment of $600K that could take 5 years, gives you ballpark $60,000 more in cost of money assuming a 2% yearly interest rate. That's another $12 per dose for a total of $132. Let's call it $150 per dose to be safe. 
 
Since R&D has been done on the public dime, the question becomes what the cost of patent licensing from universities would be. Let's assume $5,000 license fee per dose, which gives the University something for the license.

Each disease has its own market size and dynamic. Some of these are rare diseases.

In the case of LCA above, there are roughly 4000 patients in the USA and Canada, and another 9000 in Europe and 1500 more in Japan. One should expect that no more than 50% of potential patients will make use of the treatment in the first 5 years, and that may be optimistic. But there's a problem, because there are 11 different genetic versions of LCA known. Not having a breakdown, we should assume they are roughly equally distributed. So most likely, in primary markets of the USA, Canada, Europe and Japan, there are only 1300 or so patients. That means roughly 650 patients will take this treatment in the first 5 years. A different version has to be made for each type of LCA.

Note also that due to low patient numbers, the clinical trials will seriously cut into the patient pool. I think we should subtract at least 100 patients as clinical trial free treatments. So that's 550 net in the first five years, worldwide. Of those, roughly 180 were in the USA. So after clinical trial in the USA, there will be 80 patients left, suitable for this treatment. (Note also that I am assuming the cost of clinical trials will be picked up by NIH.)

Multiplying that out gives us a ballpark return for the University of $2.75 million in 5 years, worldwide. Subtract from that their cost to patent worldwide which is on the order of $250,000. So net $2.5 million. That's seems reasonable.

Given that, the base cost per treatment goes up. Let's assume we have to amortize over 5 years among 550 patients the $660,000 production cost.  That's about $1200 each, so call it $1400 manufacturing cost per dose. That gives us $6400 base cost.

Who will distribute this? It's a small enough product that conceivably it could be done through the university directly. With markup, the cost per treatment could be as low as $12K, or as high as $50K. If a university handled production, storage and distribution worldwide it would probably be on the $12K side and the university would double their income from it. That would be worth it to them. If a Merck, Roche or Pfizer handled it, they need to generate more to pay for educating their sales channel, etc. and then make enough for the product to matter to them. At the $50,000 price point, it would make them $24 million over 5 years, or a almost $5 million per year.

Avatar of: mlerman

mlerman

Posts: 25

December 25, 2012

 

When working at NCI in 2006-2010 I invented and developed (among other approaches including new vaccines, antibodies, specific drugs) the combined gene therapy of cancer (CGTC). Everything I proposed was rejected and I was forced to retire in 2008. The CGTC employs two known TSG, one delivered to HPSC, the other to CSC (cancer stem cells). The genes should be expressed from non integrating episomal vectors. The vectors and the delivery vehicles were described and developed. I have written on this in comments to Science, Nature, Provocative Questions (NCI) and finally to the WH program on Bioeconomy (WH, web site, also now on the web by GOOGLE search). I need $1,000.000 to implement this cancer cure. I understand fully the social consequences of finally curing cancer. Michael Lerman, M.D., Ph.D.   

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Synthetic Genomics
Synthetic Genomics
Advertisement
Life Technologies